论文部分内容阅读
目的探讨急性冠状动脉综合征(ACS)早期分别应用不同剂量辛伐他汀的临床疗效和安全性。方法将11 3例临床确诊为ACS患者随机单盲分为两组:A组(20 mg组,56例)和B组(40 mg组,57例),随访12 W,观察调脂疗效,药物不良反应及心脏事件的发生率。结果①两组服药后4 W、12 W的总胆固醇(TC),低密度脂蛋白胆固醇(LDL-C)水平均较治疗前明显降低,B组较A组降低更明显;②B组累计心脏事件发生率较A组明显减少;③两组均无严重不良反应。结论 ACS患者早期应用辛伐他汀40mg/d,能更有效地降脂,提高达标率,明显抑制炎症因子,减少心脏事件的发生率,且安全,耐受性良好。
Objective To investigate the clinical efficacy and safety of different doses of simvastatin in early stage of acute coronary syndrome (ACS). Methods One hundred and eleven patients with clinically diagnosed ACS were randomly divided into two groups: group A (20 mg group, n = 56) and group B (40 mg group, n = 57), followed up for 12 weeks. Adverse reactions and the incidence of cardiac events. Results ① The levels of total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) at 4 and 12 weeks after treatment in both groups were significantly lower than those before treatment and significantly lower in group B than those in group A. ② The cumulative cardiac events The incidence was significantly reduced compared with the A group; ③ no serious adverse reactions in both groups. Conclusions The early application of simvastatin 40 mg / d in patients with ACS can reduce the lipid more effectively, improve the compliance rate, obviously inhibit the inflammatory factors, reduce the incidence of cardiac events, and have good safety and tolerability.